Law360 (September 25, 2020, 5:04 PM EDT) -- On Sept. 13, President Donald Trump issued a long-anticipated executive order on international reference drug pricing, signaling that rulemaking on the prices that the Medicare program pays for drugs may be underway again. The executive order introduces some new concepts for international reference drug pricing, including, significantly, application to Medicare Part D as well as Part B, and an even lower international reference price.
However, like its predecessor pronouncements, the executive order provides no specifics for implementation, leaving it unlikely that any changes to the Medicare program contemplated by the executive order will go into effect, if ever, before the 2020 election, by the...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!